HER2-negative breast cancer
Itovebi With Palbociclib and Fulvestrant Approved for Some Advanced Breast Cancer Patients
The FDA has approved inavolisib (Itovebi, Genentech) with palbociclib and fulvestrant for adults with ...
OCTOBER 11, 2024
FDA Approves Truqap With Fulvestrant for Breast Cancer
The FDA approved capivasertib (Truqap, AstraZeneca) with fulvestrant for adult patients with hormone receptor ...
NOVEMBER 17, 2023
Adding Palbociclib to Endocrine Therapy Shows No Benefit in Study
There is no benefit to adding palbociclib to endocrine therapy in patients with early hormone receptor ...
MARCH 16, 2022
FDA Approves Talzenna for gBRCAm HER2– Breast Ca
The FDA approved Talzenna, a poly(adenosine diphosphate–ribose) polymerase inhibitor, for patients with ...
OCTOBER 18, 2018
AI Therapy Improves Distant Relapse Outcomes in HER2– Breast Cancer
HER2-negative status in breast cancer patients may be an indicator that up-front aromatase inhibitor (AI) therapy, ...
JUNE 23, 2017
Study Evaluates PET/CT, MRI for Breast Cancer Monitoring
In patients with ER-positive/HER2-negative breast cancer, PET/CT may be more useful than MRI for monitoring tumor ...
JUNE 13, 2017
Beta Blockers May Improve PFS in Breast Cancer Patients
Beta blockers may increase progression-free survival (PFS) in HER2-negative and triple-negative breast cancer ...
JUNE 13, 2017
Multigene Assay May Change Treatment Recommendations in Early Breast Cancer
Recurrence scores may influence the kind of treatment that is recommended to ER-positive/HER2-negative breast ...
MAY 25, 2017
Mouthwash May Prevent Stomatitis in Certain Breast Cancer Patients
Dexamethasone mouthwash may prevent stomatitis in patients who are treated with everolimus (Afinitor, Novartis) and ...
MAY 25, 2017
Ribociclib Safely Prolongs PFS in Advanced Breast Cancer
Amsterdam—First-line treatment with ribociclib plus letrozole prolongs progression-free survival (PFS) in ...
MAY 8, 2017
Higher Rates of Distant Metastasis, Mortality in Breast Cancer Patients
Rates of distant metastasis and mortality were found to be higher among breast cancer patients with hormone ...
APRIL 28, 2017
Ruxolitinib + Capecitabine Improves ORR But Not PFS or OS in HER2- Breast Ca With Elevated CRP
In patients with advanced HER2-negative breast cancer with elevated C-reactive protein (CRP) levels, adding ...
APRIL 28, 2017